Breaking Barriers With Basal Insulin Biosimilars in Type 2 Diabetes.

Despite increases in the availability and effectiveness of other therapies, insulin remains an essential treatment for approximately 30 million people with type 2 diabetes worldwide. The development of biosimilars has created the potential for significant health care cost savings and may lead to greater access to basal insulin for vast populations. In this review, we discuss evidence demonstrating equipoise between basal insulin biosimilars and the patented analogs they may replace.

Informations de copyright

© 2023 by the American Diabetes Association.

Déclaration de conflit d'intérêts

S.H. has undertaken consultancy for Eli Lilly, Mylan, Novo Nordisk, Sanofi, Takeda, and Zealand Pharma, and is currently on speakers bureaus for MSD and Novo Nordisk. J.F.R. is a speaker for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck, Novo Nordisk, and Sanofi. S.T. has received research honoraria from AstraZeneca, Eli Lilly, and Novo Nordisk and is a consultant/speaker at AstraZeneca, Boehringer Ingelheim, Eli Lilly, and Novo Nordisk. W.H. has been a paid speaker for AstraZeneca, Boehringer Ingelheim, MSD, Mylan, Napp, and Novo Nordisk. S.D. has been a paid consultant/speaker for Abbott, AstraZeneca, Eli Lilly, MSD, Mylan, Napp, Novo Nordisk, Sanofi, and Viatris. T.B. has received clinical research support from AstraZeneca, Eli Lilly, Lexicon, Merck, Mylan, Novo Nordisk, and Sanofi and speaker fees from Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, Novo Nordisk, and Sanofi. No other potential conflicts of interest relevant to this article were reported.